Oct 9 2007
NanoBio Corporation, a biopharmaceutical company developing and commercializing novel products for the prevention and treatment of infectious diseases, has been honored as a recipient of the 2007 Innovation Michigan award.
The annual business awards honor Michigan companies whose innovative products, processes or business strategies distinguish them from their peers. The awards are bestowed by Michigan Business Review, and its recipients and have included Fortune 500, mid and small businesses from across many industries in the state.
NanoBio's award was bestowed in the category of "innovative process," the way in which the company conducts business. James Baker, NanoBio's founder and chief scientific officer, attributes the company's success to its organizational culture of openness and a team-oriented approach to decision making.
"I've always believed that everyone in an organization is important to accomplishing our goals, and that everyone can provide input that is helpful," Baker said. "Given the complexity of our technology and the diversity of the products we are developing, it is essential that we utilize all of our human resources to achieve success."
NanoBio is developing a pipeline of products that uses nano-scale particles to penetrate the skin's pores and hair shafts to attack bacteria, viruses and fungi. The same platform is being applied to a diverse range of needle-free mucosal vaccines designed to combat influenza, anthrax, hepatitis, and numerous other diseases.
The NanoStat(TM) technology underlying their products utilizes high-energy particles to selectively seek and destroy pathogens without introducing harsh chemicals or systemic side effects. The company's lead products are topical lotions to eradicate cold sores and nail fungus. Phase 2 data for the products - NB-001 and NB-002 -- are expected in early 2008.
NanoBio has been awarded four U.S. and international patents and numerous other patent applications are pending for its NanoStat(TM) technology. NanoBio holds the exclusive rights to license each of the products it develops.